Aliskiren and losartan trial in non-diabetic chronic kidney disease | Zendy

Keng-Thye Woo | Zendy; HuiLin Choong | Zendy; KokSeng Wong | Zendy; Han-Kim Tan | Zendy; Marjorie Foo | Zendy; Stephanie FookChong | Zendy; Evan J.C. Lee | Zendy; Anantharaman Vathsala | Zendy; Grace S.L. Lee | Zendy; Choong-Meng Chan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aliskiren and losartan trial in non-diabetic chronic kidney disease

Author(s) -

Keng-Thye Woo,

HuiLin Choong,

KokSeng Wong,

Han-Kim Tan,

Marjorie Foo,

Stephanie FookChong,

Evan J.C. Lee,

Anantharaman Vathsala,

Grace S.L. Lee,

Choong-Meng Chan

Publication year - 2014

Publication title -

journal of the renin-angiotensin-aldosterone system

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.457

H-Index - 46

eISSN - 1752-8976

pISSN - 1470-3203

DOI - 10.1177/1470320313510584

Subject(s) - aliskiren , losartan , medicine , urology , proteinuria , kidney disease , diabetic nephropathy , diabetes mellitus , pharmacology , kidney , endocrinology , renin–angiotensin system , blood pressure

This is a report of a clinical trial on the therapeutic efficacy and safety of combined aliskiren and losartan (an angiotensin II receptor blocker (ARB)) versus aliskiren alone and ARB alone in non-diabetic chronic kidney disease (CKD) over a 3-year period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research